There are limited data to guide the use of anticoagulation in cirrhotic patients prior to liver transplantation especially when using direct oral anticoagulants. In this article, we present 2 cases. The first is a 42-year-old male with cirrhosis complicated by portal vein thrombosis (PVT) treated with dabigatran who underwent orthotopic liver transplantation without complication. The second case is a 65-year-old man with alcoholic cirrhosis complicated by PVT treated with dabigatran who underwent orthotopic liver transplantation and required reoperation for surgical bleeding. Both patients were treated with dabigatran’s reversal agent idarucizumab prior to incision. In this case series, we discuss the treatment of cirrhotic patients with various anticoagulants, considerations for anticoagulant selection and reversal prior to liver transplant, and questions for future investigation.
NorthupPReutemannB. Management of coagulation and anticoagulation in liver transplantation candidates. Liver Transpl. 2018;24:1119-1132.
2.
Abdel-RazikAMousaNElhelalyRTawfikA. De-novo portal vein thrombosis in liver cirrhosis: risk factors and correlation with the Model for End-stage Liver Disease scoring system. Eur J Gastroenterol Hepatol. 2015;27:585-592.
3.
HeoYA. Andexanet alfa: first global approval. Drugs. 2018;78:1049-1055.
4.
IntagliataNMaitlandHPellitierSCaldwellS. Reversal of direct oral anticoagulants for liver transplantation in cirrhosis: a step forward. Liver Transpl. 2017;23:396-397.
5.
LichvarABPierceDRSalernoDKlemPWaldmanGParkJM. Utilization of direct-acting oral anticoagulation in solid organ transplant patients: a national survey of institutional practices. Clin Transplant. 2020;34:e13853.
6.
VanRGrottkeOSpronkH. Measurement of dabigatran in standardly used clinical assays, whole blood viscoelastic coagulation, and thrombin generation assays. Clin Lab Med. 2014;34:479-501.
7.
HawesEDealAFunk-AdcockD, et al. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost. 2013;11:1493-1502.
8.
HaddadTMHamdehSKanmanthareddyAAllaVM. Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: a systematic review and meta-analysis. Diabetes Metab Syndr. 2017;11(suppl 1):S209-S216.
9.
KuoLChaoTFLiuCJ, et al. Liver cirrhosis in patients with atrial fibrillation: would oral anticoagulation have a net clinical benefit for stroke prevention?J Am Heart Assoc. 2017;6:e005307.
10.
HuJXuYHeZ, et al. Increased risk of cerebrovascular accident related to non-alcoholic fatty liver disease: a meta-analysis. Oncotarget. 2017;9:2752-2760.
11.
ZhangXQiXYoshidaEM, et al. Ischemic stroke in liver cirrhosis: epidemiology, risk factors, and in-hospital outcomes. Eur J Gastroenterol Hepatol. 2018;30:233-240.
12.
SogaardKKHorvath-PuhoEGronbaekHJepsenPVilstrupHSorensenHT. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case control study. Am J Gastroenterol. 2009;104:96-101.
13.
WuHNguyenGC. Liver cirrhosis is associated with venous thromboembolism among hospitalized patients in a nationwide US study. Clin Gastroenterol Hepatol. 2010;8:800-805.
14.
GulleyDTealESuvannasankhaAChalasaniNLiangpunsakulS. Deep vein thrombosis and pulmonary embolism in cirrhosis patients. Dig Dis Sci. 2008;53:3012-3017.
15.
SøgaardKKHorváth-PuhóEMontomoliJVilstrupHSorensenHT. Cirrhosis is associated with an increased 30-day mortality after venous thromboembolism. Clin Transl Gastroenterol. 2015;6:e97.
16.
PriyankaPKupecJTKrafftMShahNAReynoldsGJ. Newer oral anticoagulants in the treatment of acute portal vein thrombosis in patients with and without cirrhosis. Int J Hepatol. 2018;2018:8432781.
17.
WernerKTSandoSCareyEJ, et al. Portal vein thrombosis in patients with end stage liver disease awaiting liver transplantation: outcome of anticoagulation. Dig Dis Sci. 2013;58:1776-1780.
18.
DelgadoMGSeijoSYepesI, et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol. 2012;10:776-783.
19.
PettinariIVukoticRStefanescuH, et al; BO-LIVES (BOlogna LIVEr vascular Studies). Clinical impact and safety of anticoagulants for portal vein thrombosis in cirrhosis. Am J Gastroenterol. 2019;114:258-266.
20.
LoffredoLPastoriDFarcomeniAVioliF. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis. Gastroenterology. 2017;153:480-487.e1.
21.
QiXde StefanoVLiHDaiJGuoXFanD. Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. Eur J Intern Med. 2015;26:23-29.
22.
ChenHLiuLQiX, et al. Efficacy and safety of anticoagulation in more advanced portal vein thrombosis in patients with liver cirrhosis. Eur J Gastroenterol Hepatol. 2016;28:82-89.
23.
SenzoloMSartoriTMRossettoV, et al. Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int. 2012;32:919-927.
24.
VillaECammaCMariettaM, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology. 2012;143:1253-1260.e4.
25.
DeLeveLDVallaDCGarcia-TsaoG; American Association for the Study Liver Diseases. Vascular disorders of the liver. Hepatology. 2009;49:1729-1764.
26.
ChungJWKimGHLeeJH, et al. Safety, efficacy, and response predictors of anticoagulation for the treatment of nonmalignant portal-vein thrombosis in patients with cirrhosis: a propensity score matching analysis. Clin Mol Hepatol. 2014;20:384-391.
27.
WangZJiangMSZhangHL, et al. Is post-TIPS anticoagulation therapy necessary in patients with cirrhosis and portal vein thrombosis? A randomized controlled trial. Radiology. 2016;279:943-951.
28.
AmitranoLGuardascioneMAMenchiseA, et al. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol. 2010;44:448-451.
29.
CuiSBShuRHYanSP, et al. Efficacy and safety of anticoagulation therapy with different doses of enoxaparin for portal vein thrombosis in cirrhotic patients with hepatitis B. Eur J Gastroenterol Hepatol. 2015;27:914-919.
30.
WangJChaiJZhangJ. Anticoagulation treatment of portal vein thrombosis in a patient with cirrhosis awaiting liver transplantation. Medicine (Baltimore). 2018;97:e11183.
31.
WeinbergEPaleckiJReddyKR. Direct-acting oral anticoagulants (DOACs) in cirrhosis and cirrhosis-associated portal vein thrombosis. Semin Liver Dis. 2019;39:195-208.
32.
ReillyPvan RynJGrottkeOGlundSStangierJ. Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects. Am J Emerg Med. 2016;34(11 suppl):26-32.
33.
NagaokiYAikataHDaijyoK, et al. Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis. Hepatol Res. 2018;48:51-58.
34.
HanafyASAbd-ElsalamSDawoudMM. Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis. Vascul Pharmacol. 2019;113:86-91.
35.
HumJShatzelJJJouJHDelougheryTG. The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis. Eur J Haematol. 2017;98:393-397.
36.
IntagliataNMHenryZHMaitlandH, et al. Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation. Dig Dis Sci. 2016;61:1721-1727.
37.
De GottardiATrebickaJKlingerC, et al. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. Liver Int. 2017;37:694-699.
38.
KunkPRCollinsHPalkimasSIntagliataNMMaitlandHS. Direct oral anticoagulants in patients with cirrhosis appear safe and effective. Blood. 2016;128:3827.
TummalaRKavtaradzeAGuptaAGhoshRK. Specific antidotes against direct oral anticoagulants: a comprehensive review of clinical trials data. Int J Cardiol. 2016;214:292-298.
43.
StangierJRathgenKStähleHMuzarD. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate. Clin Pharmacokinet. 2010;49:259-268.
44.
DourosAAzoulayLYinHSuissaSRenouxC. Non-vitamin K antagonist oral anticoagulants and risk of serious liver injury. J Am Coll Cardiol. 2018;71:1105-1113.
45.
ReillyPALehrTHaertterS, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014;63:321-328.
46.
MooreTCohenMMattisonD. Dabigatran, bleeding, and the regulators. BMJ. 2014;349:g4517.
47.
SolbeckSMeyerMASJohannsonP, et al. Monitoring of dabigatran anticoagulation and its reversal in vitro by thrombelastography. Int J Cardiol. 2014;176:794-799.
48.
PipilisAMakrygiannisSAnagnostouG, et al. Dabigatran plasma levels, aPTT and thromboelastography in patients with AF: implications for allowing early non-elective surgical procedures. J Thromb Thrombolysis. 2017;44:9-13.
49.
TralhãoAAguiarCFerreiraJ, et al. Dabigatran reversal with idarucizumab in a patient undergoing heart transplantation: first European report. Thromb J. 2017;15:23.
50.
MarinoKKSantiagoRADewRB3rd, et al. Management of dabigatran-associated bleeding with two doses of idarucizumab plus hemodialysis. Pharmacotherapy. 2016;36:e160-e165.
51.
PollackCJrReillyPEikelboomJ, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373:511-520.
52.
PollackCJrReillyPvan RynJ, et al. Idarucizumab for dabigatran reversal—full cohort analysis. N Engl J Med. 2017;377:431-441.
EikelboomJQuinlanDvan RynJWeitzJ. Idarucizumab: the antidote for reversal of dabigatran. Circulation. 2015;132:2412-2422.
55.
SarodeRMillingTJJrRefaaiMA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128:1234-1243.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
